Search or

𝛼SK

ENTITY

Sihuan Pharmaceutical Hldgs (460 HK)

74

Analysis

Health Care • China

Sihuan Pharmaceutical Holdings Group Ltd. researches and develops cardiocerebral vascular drugs in China. The Company drugs address needs in the areas of anti-infective, metabolism, cardiovascular system, oncology and nervous system.

more

Refresh

Exchange Announcement • 08 Dec 2025 16:44

Voluntary Announcement -Xuanyuening, An Innovative Drug, First Included In The Nrdl

Exchange Announcement • 08 Dec 2025 16:38

Voluntary Announcement-Successful Renewal And Inclusion Of The Innovative Drug Anjiuwei In The 2025 Nrdl

Exchange Announcement • 18 Nov 2025 22:50

Voluntary Announcement - Proposed Implementation Of The H Share Full Circulation By Xuanzhu Biopharma

Exchange Announcement • 30 Oct 2025 08:00

Voluntary Announcement-Sihuan Pharmaceutical Signs Cooperation Agreement With U.S.-Based Abalone Bio To Jointly Develop A New-Generation Innovative Therapy For Weight Loss And Muscle Gain, Further Deepening Its Layout In The Gpcr Target Field

Exchange Announcement • 28 Oct 2025 16:36

Voluntary Announcement - Ng-350a Granted Fast Track Designation By The U.S. Fda

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.59.10

x